Starboard Value Activist Hedge Fund has asked an attorney-at-law to investigate the level of shareholder support for Bristol-Myers Squibb (NYSE: BMY) as part of its Celgene (NASDAQ: CELG) Purchase Agreement. reports $ 74 to Reuters.
Starboard has not yet decided whether it would oppose the transaction, but Bristol-Myers shareholders will vote in April.
The acquisition would be the largest pharmaceutical transaction ever concluded and would unite two major vendors of anti-cancer drugs.
Previously: Starboard would have taken a stake in Bristol-Myers Squibb (February 2, 2019)